Curis, Inc...announced that it will host a webcast on Wednesday, July 22 at 8:30 a.m. ET to...provide updated guidance on year-end data in the TakeAim CLL study, its ongoing Phase 2 study in Chronic Lymphocytic Leukemia (Curis Press Release) - Jul 22, 2026 - "TakeAim CLL: Today, the Company announced that the number of patients consented has increased to 10, with the first five expected to be dosed by the end of July. The company is also increasing its guidance for year-end CLL data from 5 patients to 5-10 patients in December 2026."
P2 data • Trial status • Chronic Lymphocytic Leukemia
|